Thursday, 15 October 2026European Markets

J.MARTINS,SGPS And 2 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Loading stream...

(VIANEWS) - J.MARTINS,SGPS (JMT.LS), AZERION (AZRN.AS), KID (KID.OL) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. J.MARTINS,SGPS (JMT.LS)

17.7% sales growth and 28.68% return on equity

Jerónimo Martins, SGPS, S.A. operates in the food distribution and specialized retail sectors in Portugal, Poland, and Colombia. The company operates through Portugal Retail; Portugal Cash & Carry; Poland Retail; Colombia Retail; and Others, Eliminations and Adjustments segments. It operates food stores under the Biedronka name; and a chain of health and beauty stores under the Hebe banner in Poland, as well as food stores under the Ara name in Colombia. The company also operates supermarkets under the Pingo Doce banner; and cash and carry stores under the Recheio name in Portugal, and under the Bodega del Canasto name in Colombia. In addition, it operates restaurants under the Pingo Doce name; para-pharmacies and petrol stations under Bem-Estar brand; and clothing under Code brand. Further, the company operates coffee shops and kiosks under the Jeronymo name; and chocolates and confectionary retail stores under Hussel name. Additionally, the company engages in human resources top management, real estate management and administration, training, and saline brackish waters aquaculture; wholesale of fruit and vegetables; retail management, consultancy, and logistics activities; purchase and sale of real estate; growing of crops and farming of animals; retail sale of health and beauty products; manufacture of milk and dairy products; rental of air transport equipment; and provision of business portfolio management, financial, and sea passenger water transport services. It is also involved in the trading and distribution of consumer goods; retail and wholesale of non-food products; other business support service activities; and provision of services in the area of wholesale and retail distribution. The company was founded in 1792 and is headquartered in Lisbon, Portugal. Jerónimo Martins, SGPS, S.A. operates as a subsidiary of Sociedade Francisco Manuel Dos Santos, S.G.P.S., S.A.

Earnings Per Share

As for profitability, J.MARTINS,SGPS has a trailing twelve months EPS of €1.07.

PE Ratio

J.MARTINS,SGPS has a trailing twelve months price to earnings ratio of 15.66. Meaning, the purchaser of the share is investing €15.66 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 28.68%.

Volume

Today's last reported volume for J.MARTINS,SGPS is 162322 which is 82.43% below its average volume of 924225.

More news about J.MARTINS,SGPS.

2. AZERION (AZRN.AS)

10.7% sales growth and 23.87% return on equity

Azerion Group N.V. operates a digital entertainment and media platform in the Netherlands, Germany, France, Great Britain, Ireland, Italy, other Nordic and European countries, the United States, the United Arab Emirates, and internationally. The company operates in two segments, Platform and Premium Games. Its integrated platform offers technology solutions to automate the purchase and sale of digital advertising inventory for advertisers, publishers, and game creators, as well as to develop, publish, distribute, and operate online social and casual games, and digital content. The company also operates Hawk, a digital advertising technology platform. Azerion Group N.V. was founded in 2013 and is headquartered in Schiphol-Rijk, the Netherlands.

Earnings Per Share

As for profitability, AZERION has a trailing twelve months EPS of €0.17.

PE Ratio

AZERION has a trailing twelve months price to earnings ratio of 8.47. Meaning, the purchaser of the share is investing €8.47 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 23.87%.

More news about AZERION.

3. KID (KID.OL)

7.5% sales growth and 29.84% return on equity

Kid ASA, together with its subsidiaries, operates as a home textile retailer in Norway, Sweden, Finland, and Estonia. It designs, sources, markets, and sells a range of home and interior products, including textiles, curtains, bed linens, home accessories, decorations, furniture, and other interior products through retail stores and online platforms. The company provides its products under the Kid, Hemtex, Dekosol, Nordun, and Premium Collection brands. It also offers logistics services. The company was formerly known as Nordisk Tekstil Holding AS and changed its name to Kid ASA. Kid ASA was founded in 1937 and is headquartered in Lier, Norway.

Earnings Per Share

As for profitability, KID has a trailing twelve months EPS of kr8.94.

PE Ratio

KID has a trailing twelve months price to earnings ratio of 16.33. Meaning, the purchaser of the share is investing kr16.33 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.84%.

Yearly Top and Bottom Value

KID's stock is valued at kr146.00 at 02:20 EST, below its 52-week high of kr160.00 and way above its 52-week low of kr79.10.

Sales Growth

KID's sales growth is 10.2% for the present quarter and 7.5% for the next.

More news about KID.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com